In a move that marks the most significant shift in federal drug policy in over half a century, the Department of Justice officially announced today that it has moved to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).
The announcement follows a formal recommendation from the Department of Health and Human Services (HHS) and a rigorous review by the Office of Legal Counsel.
For Ohio—a state currently navigating a major regulatory transition under Senate Bill 56—this federal shift represents a massive economic catalyst for the local medical cannabis industry.
“Accepted Medical Use”: The Language of the Order
The DOJ’s decision hinges on the formal recognition that cannabis no longer meets the criteria for the most restrictive drug category. In the official announcement, the Justice Department stated that the Attorney General has submitted a notice of proposed rulemaking that “recognizes that marijuana has a currently accepted medical use in treatment in the United States.”
The order further clarifies that the DEA’s review found cannabis has a “potential for abuse less than the drugs or other substances in schedules I and II.” This shift effectively ends the federal government’s 50-year stance that the plant has “no accepted medical value,” a label that has long hindered research and professionalization within the industry.
As reported by Marijuana Moment, this move is a direct response to President Biden’s 2022 directive to review how cannabis is scheduled under federal law. By moving to Schedule III, it joins the ranks of other regulated substances like ketamine and Tylenol with codeine, which are recognized for their therapeutic benefits but remain subject to federal oversight.
The 280E “Tax Cliff” and Ohio’s Economic Future
For Ohio’s licensed cultivators and dispensaries, the most immediate impact of Schedule III is the removal of the Internal Revenue Code Section 280E. Under Schedule I, cannabis businesses were legally barred from taking standard business deductions—such as rent, payroll, and marketing—often resulting in effective tax rates as high as 70 to 90 percent.
According to tax experts interviewed by Forbes, the transition to Schedule III means Section 280E will no longer apply to state-legal cannabis businesses. This allows Ohio operators to finally reinvest in infrastructure, hire more staff, and potentially lower prices for patients who have long complained about the high cost of medicine in the Buckeye State.
Major industry players, including multi-state operators like Trulieve, have noted in public statements that this reclassification provides a clear pathway for operators to register with the DEA, effectively bridging the gap between state legality and federal recognition.
Why Schedule III is a “Middle Ground” with Drawbacks
While the industry celebrates the tax relief, drug policy advocates warn that Schedule III is a compromise that leaves many critical issues unresolved. Journalistic analysis from The New York Times highlights that rescheduling is not the same as federal legalization. Because cannabis remains a controlled substance, possession without a valid federal prescription could technically still lead to federal charges, creating a confusing legal landscape for Ohio’s adult-use consumers.
A primary concern among advocates is the “pharmaceuticalization” of the plant. Since Schedule III substances are traditionally dispensed through pharmacies via FDA-approved channels, there is a lingering fear that the FDA could eventually demand that state-licensed dispensaries meet the same rigorous Good Manufacturing Practices (GMP) as traditional drug manufacturers. This could favor large pharmaceutical firms over the small-business owners currently operating in Ohio’s program.
Furthermore, rescheduling does not address restorative justice. It does not automatically expunge past federal records or provide a mechanism for the release of those currently incarcerated for non-violent cannabis offenses. This has led many to argue that the DOJ’s action, while historic, prioritizes corporate profitability over social equity.
The Case for Descheduling: The “Gold Standard”
Many legal experts and reform groups argue that the only way to truly align federal and state law is to deschedule cannabis entirely—removing it from the Controlled Substances Act altogether and regulating it like alcohol or tobacco.
Descheduling would grant Ohio full autonomy to regulate its market without the threat of DEA interference. As noted by the Drug Policy Alliance, only descheduling would allow for true interstate commerce, potentially opening the door for Ohio’s agricultural sector to export Buckeye-grown products to other states. Perhaps most importantly, descheduling removes the “controlled substance” label that still fuels discrimination in employment, housing, and medical care for patients.
What This Means for Ohio’s Cannabis Policy Landscape
The timing of the federal announcement is particularly relevant for Ohioans following the implementation of Senate Bill 56 (SB 56). This state law recently merged medical and adult-use programs under the Division of Cannabis Control and introduced strict potency caps.
Because Schedule III specifically recognizes “medical use,” it creates a protected federal status for only the medical side of Ohio’s market. This could lead to a two-tiered system where medical patients gain access to potential insurance-reimbursable options and stronger legal protections, while adult-use consumers remain in a federal legal “gray area.” Additionally, since SB 56 prohibits the “smuggling” of cannabis from other states like Michigan, the continued federal ban on interstate commerce under Schedule III reinforces Ohio’s “closed-loop” model for the time being.
The Road Ahead: Considering Descheduling
The DOJ isn’t stopping at this immediate reclassification for medical products. The administration also announced that it will launch a new administrative hearing process beginning on June 29, 2026, to consider “broader rescheduling” of cannabis, which could address adult-use and decriminalization more directly.
As reported by CBS News, this process will provide a “legally compliant pathway” to evaluate broader changes to the plant’s status under federal law. As the federal government begins to professionalize the industry, the next chapter for MedicateOH will focus on how these changes affect the patient experience, specifically regarding product safety, standardized testing, and the expansion of medical research.
For now, the message from Washington is that the era of total prohibition is ending, but advocates know the fight for a truly equitable and open market is just beginning. MedicateOH will continue to follow this story.
To stay up to date on the latest cannabis news, patient and consumer rights in Ohio:
Subscribe to our Newsletter: Join the MedicateOH & MedicateKY Community
Join our Social Channels: Connect with us on social media to be part of the discussion: Facebook |Instagram |LinkedIn |Reddit
Federal “Green Light”: DOJ Reschedules Cannabis to Schedule III
